#fig2

The first photo display all the images which are incorporated within my final photomontage. When I have used only details of images, I have marked the sections of interest.  The second photos shows the editing process of Fig.2. The developing process of Fig.2 (final print) was pretty slow. At first, I wasn’t sure about which images to use nor on which areas to focus, not even on which type of composition I wanted to create. With the passing of time, I was able to mature an idea in my mind. I kept experimenting, dragging images on top of one another, applying transparencies, setting rulers..then, I flipped the document. The whole collage started to make sense, and such allowed me to complete Fig.2 in a couple of hours. 

TRIK / 'voorhangprocedure'. nr.2 in de serie 'Hou Het Helder' cartoons, in opdracht van de @gemeentehaarlem ter bevordering van helder taalgebruik op de (gemeentelijke) werkvloer. #houhethelder #voorhangprocedure #trik #triknologi #absurdism #jargon #gemeentehaarlem #fig2

🌟A beautiful new work by Amy Stephens for her solo show @grundyartgallery #blackpool as part of #fig-futures until 12 of May #fig2 @fig2london #contemporary #art @outsetart @artfund @fatosustek @bpoolcouncil Image: @amystephens7 ‘South | Shore’, 2018 -, Archival pigment print, stainless steel #amystephens #soloshow #contemporaryart #contemporaryartist #contemporarysculpture #fig2 #figfutures #victorian #shelter (at Blackpool)

By juan carlos osorno on Flickr

Photos from http://www.fig2.co.uk/

Information sourced from *CDC*: *Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older — United States, 2013* *February 1, 2013 / 62(01);9-19* ACIP Adult Immunization Work Group Carolyn B. Bridges, MD, LaDora Woods, Tamera Coyne-Beasley, MD *Corresponding contributor:* Carolyn B. Bridges, [email protected], 404-639-8689. [Full-text MMWR Article| Adult Vaccination Schedule by Vaccine and Age Group| Vaccinations for Adults Based on Medical and Other Conditions| Contraindications and Precautions to Commonly Used Vaccines in Adults ] [EXCERPTS] Current levels of vaccination coverage among adults are low (*1*). Health-care providers should be aware of the importance of routinely assessing patients' vaccination histories and recommending and providing routinely recommended vaccines. A strong recommendation from a health-care provider is associated with increased uptake of vaccines (*2 ,3*). Other interventions shown to increase vaccine uptake, such as implementation of reminder/recall systems and standing orders, have been summarized by the Community Guide( *3*). The Advisory Committee on Immunization Practices (ACIP) annually reviews and updates the adult immunization schedule, which is designed to provide vaccine providers with a summary of existing ACIP recommendations regarding the routine use of vaccines for adults (Figure 1and Figure 2). The adult schedule also includes a table summarizing the primary contraindications and precautions for routinely recommended vaccines (Table ). The primary updates include adding information for the first time on the use of *13-valent pneumococcal conjugate vaccine (PCV13)*and the timing of administration of PCV13 relative to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults (*4*). The schedulealso clarifies which adults need 1 or 2 doses of PPSV23 before age 65 years. Other changes to the PPSV23 footnoteinclude adding information regarding recommendations for vaccination when vaccination status is unknown. *Pneumococcal conjugate 13-valent vaccination (PCV13)* - Adults aged 19 years or older with immunocompromising conditions (including chronic renal failure and nephrotic syndrome), functional or anatomic asplenia, CSF leaks or cochlear implants, and who have not previously received PCV13 or PPSV23 should receive a single dose of PCV13 followed by a dose of PPSV23 at least 8 weeks later. - Adults aged 19 years or older with the aforementioned conditions who have previously received one or more doses of PPSV23 should receive a dose of PCV13 one or more years after the last PPSV23 dose was received. For those that require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years since the most recent dose of PPSV23. - When indicated, PCV13 should be administered to patients who are uncertain of their vaccination status history and there is no record of previous vaccination. - Although PCV13 is licensed by the Food and Drug Administration (FDA) for use among and can be administered to persons aged 50 years and older, ACIP recommends PCV13 for adults aged 19 years and older with the specific medical conditions noted above. *Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination* For *tetanus, diphtheria, and acellular pertussis (Tdap) vaccine*, recommendations have been expanded to include routine vaccination of adults aged 65 years and older and for pregnant women to receive Tdap vaccine with each pregnancy. - Administer one dose of Tdap vaccine to pregnant women during each pregnancy (preferred during 27–36 weeks' gestation), regardless of number of years since prior Td or Tdap vaccination. - Administer Tdap to all other adults who have not previously received Tdap or for whom vaccine status is unknown. Tdap can be administered regardless of interval since the most recent tetanus or diphtheria-toxoid containing vaccine. - Adults with an unknown or incomplete history of completing a 3-dose primary vaccination series with Td-containing vaccines should begin or complete a primary vaccination series including a Tdap dose. - For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the third dose 6–12 months after the second. - For incompletely vaccinated (i.e., less than 3 doses) adults, administer remaining doses. - Refer to the Advisory Committee on Immunization Practices (ACIP) statement for recommendations for administering Td/Tdap as prophylaxis in wound management [Td/Tdap guidelines] Vaccine providers are reminded to consult the full ACIP vaccine recommendations if they have questions and to bear in mind that additional updates might be made for specific vaccines during the year between updates to the adult schedule. Printable versions of the 2013 adult immunization schedule Adult Vaccination Schedule by Vaccine and Age Group Vaccinations Indicated for Adults Based on Medical and Other Conditions Contraindications and Precautions to Commonly Used Vaccines in Adults ACIP statements and information for specific vaccines Information about adult vaccination Adverse events from vaccination should be reported at http://www.vaers.hhs.gov or by telephone, 800-822-7967. This schedule has been approved by the American Academy of Family Physicians, the American College of Physicians, the American College of Obstetricians and Gynecologists, and the American College of Nurse-Midwives. The adult immunization schedule is published in the Annals of Internal Medicineat the same time that it is published in *MMWR*. *References* 1. CDC. Noninfluenza vaccination coverage among adults—United States, 2011. MMWR 2013;62(4). 2. CDC. Influenza vaccination coverage among pregnant women—2011–12 influenza season, United States. MMWR 2012;61:758–63. 3. Community Preventive Services Task Force. Vaccinations to prevent diseases: universally recommended vaccinations. Accessed December 21, 2012. 4. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). * MMWR* 2012;61:816–9. 5. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older — Advisory Committee on Immunization Practices (ACIP), 2012. *MMWR* 2012;61:468–70. 6. CDC. Update on use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in pregnant women.Atlanta, GA: US Department of Health and Human Services, CDC. 7. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. *Vaccine* 2012;30:1993–8. [PubMed® abstract] 8. CDC. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2011;60(No. RR-7). *Centers for Disease Control and Prevention* www.cdc.gov The above message comes from *CDC*, who is solely responsible for its content. You have received this email because you requested follow-up information to an Epocrates DocAlert® Message. For more information about DocAlert® Messages, please click here . Best wishes, The Epocrates Team 1100 Park Place, San Mateo, CA 94403